Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting 2-agonists: Results of the pacman cohort

Pharmacogenomics

Volumn 14, Issue 16, 2013, Pages 1965-1971

  Zuurhout, Miranda Jl ^a   Vijverberg, Susanne Jh ^a,b   Raaijmakers, Jan Am ^a   Koenderman, Leo ^b   Postma, Dirkje S ^c   Koppelman, Gerard H ^d   Maitland Van Der Zee, Anke Hilse ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

ADRB2; Arg16; asthma; children; corticosteroids; exacerbations; long acting adrenergic 2 receptor agonists; pharmacogenetics

Indexed keywords

ARGININE; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID;

ADRB2 GENE; ARTICLE; ASTHMA; CHILD; COHORT ANALYSIS; DISEASE CONTROL; DISEASE EXACERBATION; DRUG USE; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; SCHOOL CHILD; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPE; HOMOZYGOTE; HUMANS; MALE; RECEPTORS, ADRENERGIC, BETA-2; RISK FACTORS; TREATMENT OUTCOME;

EID: 84889016425     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.200     Document Type: Article

References (20)

1. Braman SS. The global burden of asthma. Chest 130(1 Suppl.), 4S-12S (2006).
2. Pascual RM, Bleecker ER. Pharmacogenetics of asthma. Curr. Opin. Pharmacol. 10(3), 226-235 (2010).
3. Lipworth BJ, Basu K, Donald HP et al. Tailored second-line therapy in asthmatic children with the Arg16 genotype. Clin. Sci. (Lond.) 124(8), 521-528 (2013).
4. Basu K, Palmer CN, Tavendale R, Lipworth BJ, Mukhopadhyay S. Adrenergic beta2-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. J. Allergy Clin. Immunol. 124(6), 1188-1194.e3 (2009).
5. Palmer CN, Lipworth BJ, Lee S, Ismail T, Macgregor DF, Mukhopadhyay S. Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax 61(11), 940-944 (2006).
6. Wechsler ME, Lehman E, Lazarus SC et al. Beta-adrenergic receptor polymorphisms and response to salmeterol. Am. J. Respir. Crit. Care Med. 173(5), 519-526 (2006).
7. Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town GI. Asthma exacerbations during long term beta agonist use: influence of beta2 adrenoceptor polymorphism. Thorax 55(9), 762-767 (2000).
8. Wechsler ME, Kunselman SJ, Chinchilli VM et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 374(9703), 1754-1764 (2009).
9. Bleecker ER, Nelson HS, Kraft M et al. Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am. J. Respir. Crit. Care Med. 181(7), 676-687 (2010).
10. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 370(9605), 2118-2125 (2007).
11. Bleecker ER, Yancey SW, Baitinger LA et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J. Allergy Clin. Immunol. 118(4), 809-816 (2006).
12. Koster ES, Raaijmakers JA, Koppelman GH et al. Pharmacogenetics of anti-inflammatory treatment in children with asthma: rationale and design of the PACMAN cohort. Pharmacogenomics 10(8), 1351-1361 (2009).
13. Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir. Med. 99(5), 553-558 (2005).
14. Juniper EF, Bousquet J, Abetz L, Bateman ED; GOAL Committee. Identifying 'well-controlled' and 'not well-controlled' asthma using the asthma control questionnaire. Respir. Med. 100(4), 616-621 (2006).
15. Giubergia V, Gravina L, Castanos C, Chertkoff L. Influence of beta2-adrenergic receptor polymorphisms on asthma exacerbation in children with severe asthma regularly receiving salmeterol. Ann. Allergy Asthma Immunol. 110(3), 156-160 (2013).
16. Turner SW, Khoo SK, Laing IA et al. Beta2 adrenoceptor Arg16Gly polymorphism, airway responsiveness, lung function and asthma in infants and children. Clin. Exp. Allergy 34(7), 1043-1048 (2004).
17. Dijk FN, de Jongste JC, Postma DS, Koppelman GH. Genetics of onset of asthma. Curr. Opin. Allergy Clin. Immunol. 13(2), 193-202 (2013).
18. Wu AC, Tantisira K, Li L et al. Predictors of symptoms are different from predictors of severe exacerbations from asthma in children. Chest 140(1), 100-107 (2011).
19. Israel E, Chinchilli VM, Ford JG et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364(9444), 1505-1512 (2004).
20. Hall IP, Blakey JD, Al Balushi KA et al. Beta2-adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study. Lancet 368(9537), 771-779 (2006).